Good points. Reckon LC is very confident of success ,however before seeking fast track just needs to know who we will be partnered with and with what combination drug we have the greatest chance of producing the best outcomes. Then apply for fast track for the combo therapy that will blow all other Her2 cancer therapies out of the water. With negotiations underway something could be mapped out before the end of the Ph2. Most definitely it would have to be announced once the pathway is defined and a licencing deal agreed.
IMU Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
